Ex vivo interleukin-12-priming during CD8+ T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host

MP Rubinstein, CA Cloud, TE Garrett, CJ Moore… - Journal of the American …, 2012 - Elsevier
BACKGROUND: Clinical application of adoptive T cell therapy has been hindered by an
inability to generate adequate numbers of nontolerized, functionally active, tumor-specific T
cells, which can persist in vivo. In order to address this, we evaluated the impact of
interleukin (IL)-12 signaling during tumor-specific CD8+ T cell priming in terms of
persistence and antitumor efficacy using an established B16 melanoma tumor adoptive
therapy model. STUDY DESIGN: B6 mice were injected subcutaneously with B16 melanoma …